Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Raised by Park Avenue Securities LLC

Park Avenue Securities LLC lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 19.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,521 shares of the specialty pharmaceutical company’s stock after buying an additional 412 shares during the period. Park Avenue Securities LLC’s holdings in Jazz Pharmaceuticals were worth $310,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cooper Financial Group boosted its position in Jazz Pharmaceuticals by 3.7% during the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock worth $534,000 after acquiring an additional 156 shares during the period. Wedmont Private Capital lifted its holdings in Jazz Pharmaceuticals by 37.1% in the fourth quarter. Wedmont Private Capital now owns 6,815 shares of the specialty pharmaceutical company’s stock worth $827,000 after purchasing an additional 1,843 shares during the period. Everence Capital Management Inc. bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $277,000. Centre Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $9,335,000. Finally, GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 49.8% during the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 206 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,253 shares of company stock worth $1,001,434 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ:JAZZ opened at $122.04 on Friday. The firm has a 50 day simple moving average of $122.37 and a 200 day simple moving average of $115.36. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market cap of $7.38 billion, a PE ratio of 17.19, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56.

Analysts Set New Price Targets

JAZZ has been the subject of several recent analyst reports. TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Robert W. Baird lifted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.